E-Signatures: A Built-In eQMS Solution

What is an Electronic Signature?

An electronic signature, or e-signature, is any electronic process attached to or logically associated with a record that a person adopts with the intent to sign. The U.S. ESIGN Act defines it as “an electronic sound, symbol, or process… executed or adopted by a person with the intent to sign the record,” which in practice can mean anything from typing a name to clicking a “Sign” button. What separates a legally sound signature from a simple mark is evidence like verified identity, authentication, a timestamp, and a record that cannot be altered without detection.

It is also worth distinguishing an e-signature from a digital signature. A digital signature is a specific technical implementation that uses cryptography—typically public key infrastructure (PKI) and digital certificates—to bind a verified identity to a document and invalidate the signature if the file is later changed.

Why E-Signatures Matter in Regulated Life Sciences

In pharmaceuticals, biotech, and medical devices, a signature becomes a part of a controlled record that an inspector may examine years later. In the United States, FDA 21 CFR Part 11 sets the criteria under which the agency treats electronic records and signatures as “trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.” Where a signature and its associated record meet Part 11, the FDA considers it equivalent to a full handwritten signature.

It helps to understand that Part 11 is organized into two functional halves. Subpart B governs the electronic record—the controls that keep the record accurate, protected, and reconstructable throughout its lifecycle. Subpart C governs the electronic signature—the controls that connect a verified individual to the signing action and its meaning. Subpart C is specific: each signature must be unique to one individual and never reused, identity must be verified before the signature is assigned, and non-biometric signatures must employ at least two distinct identification components such as an ID code and password. When a signer executes a series of signings during a single continuous session, the first must use all components while subsequent ones can use at least one component unique to that person; signings across separate sessions must each use all components. The system must also capture the printed name of the signer, the date and time, and the meaning of the signing—review, approval, or authorship—alongside a secure, computer-generated, time-stamped audit trail.

There is also a closed-versus-open-system distinction when it comes to e-signatures. Most eQMS deployments are closed systems, where the people responsible for the records control system access; open systems—where that is not the case—demand additional measures such as document encryption. A signing tool that exists outside a controlled environment effectively pushes its users toward open-system complexity, and this is often where general-purpose signing tools tend to fall short. A platform originally built for sales contracts may be able to handle user identities and basic logging, but it is unlikely to capture signature meaning, enforce signing-time two-factor authentication rather than login-only authentication, or produce the tamper-evident audit trail regulators expect, thereby creating further compliance burden.

Where ACE Sign Fits

ACE Sign is an electronic signature solution built specifically for the security and compliance requirements of the life sciences industry, covering 21 CFR Part 11, GDPR, and SOC 2, with AES 256-bit encryption for data at rest and in transit. It supports Part 11-compliant signatures with a complete audit trail that captures every action including signatures and corrections from initiation to completion. ACE customers can also enforce 21 CFR Part 11 compliance for all envelopes sent by the platform, guaranteeing unique signatures across every document rather than leaving compliance to per-envelope discretion.

ACE Sign addresses Subpart C directly through its signing mechanics. Signer authentication is available through email OTP or two-factor authentication, and each Part 11 signing action requires the user to enter credentials, select a role and reason, and agree to the signature disclosure before signing—capturing identity, intent, and meaning in one controlled step. A delegation feature lets an authorized user sign on a colleague’s behalf when covering for them, with the delegation itself recorded. External portal users can also execute Part 11-compliant signatures without needing an ACE license, which reduces licensing costs while preserving the compliance chain.

Functionally, ACE Sign is part of an eQMS that covers what teams expect for modern documentation and signing management—no-code configurable workflows, drag-and-drop agreement templates, bulk sending, real-time tracking, and a signing experience that works across mobile, tablet, and desktop. Critically for regulated buyers, ACE ships validated with a launch time that can be as fast as two weeks, meaning the validation evidence that inspectors expect comes with the product rather than becoming a project the customer must scope, execute, and maintain themselves.

Built In, Not Bolted On

The biggest distinction between ACE Sign and standalone competitors is architecture; while standalone platforms are excellent general-purpose signing tools, in a regulated environment they are usually isolated from the record system. Documents will then have to be routed out for signature, then routed back into a separate document management or quality system, and this bloat adds cost, handoffs, integration validation, and room for error.

ACE Sign is a native module of the ACE eQMS, which means that it pulls documents directly from ACE Docs into envelopes, so signing happens inside the same platform that manages documents, quality events, training, and inspections. An ACE Sign signature is not a detached approval event but rather captured permanently on the record it belongs to, whether that is a deviation, a CAPA, a change control, or an SOP revision. Through ACE’s parent-child architecture, that signed record stays connected to everything it spawns downstream, and this structural connection between the signature and the full record lifecycle is something a bolt-on signing tool cannot replicate.

How to Choose

For teams evaluating e-signature options, the decision comes down to matching assurance and architecture to how the record is used. If signing is confined to low-risk business paperwork that never enters a regulated workflow, a standalone tool may be sufficient. But once a signature attaches to a record governed by an FDA predicate rule—a batch record, a deviation, a controlled SOP—the evaluation criteria tighten considerably. Look for enforced unique signatures, signing-times, multi-factor authentication, captured signature meaning, and a tamper-evident audit trail. The FDA issues no compliance certifications, so every “Part 11 compliant” claim is a self-certification the buyer must verify against these specifics.

Weighed against those criteria, the strongest argument for a built-in solution like ACE Sign is that it removes the barrier between the signature and the record. Rather than validating a signing tool, validating an integration, and validating a document system separately, there exists one validated environment for the signature, the record, and every downstream action; plus, these actions all appear on the audit trail. For regulated organizations, that consolidation is an improved tool to help demonstrate compliance when an inspector asks who signed what, when, and why.